Tesamorelin is a synthetic version of hormone-releasing hormone that encourages growth hormone production. It has been approved by the FDA as a treatment for HIV-associated lipodystrophy, an illness in which fat accumulates in certain areas such as the abdomen while other parts experience fat loss.
Tesamorelin mimics GHRH, stimulating pituitary gland production and release of growth hormone. GHRH acts as a signal to the pituitary gland to make and release this hormone.
Tesamorelin, administered as a subcutaneous injection, has been demonstrated to decrease visceral adipose tissue (VAT), the fat that builds up around organs in the abdomen. This decrease in VAT has also been connected with improvements in insulin resistance and lipid profile.
Clinical trials have demonstrated the safety and effectiveness of tesamorelin for treating HIV-associated lipodystrophy. Unfortunately, it is not approved for use in other conditions such as obesity due to insufficient evidence supporting its efficacy there.
Tesamorelin can cause side effects, such as injection site reactions, joint pain and muscle ache. It’s essential to discuss the potential risks and advantages with a healthcare provider prior to beginning treatment with this medication.
Overall, tesamorelin appears to be an effective therapy for HIV-associated lipodystrophy; however, further investigation is necessary to determine its potential uses in other conditions.
This article was written by a peptide professional from Domestic Peptides. Looking for aicar for sale? Well, look no further. Welcome to Domestic Peptides where you’ll find a huge selection of Research Peptides for sale and Research Chemicals for Sale, all made in the USA.